Holen Sie sich die Stockscreener-App
15.91
9.45%
-1.66
Handel nachbörslich:
15.79
-0.12
-0.75%
Schlusskurs vom Vortag:
$17.57
Offen:
$17.27
24-Stunden-Volumen:
807.24K
Relative Volume:
4.90
Marktkapitalisierung:
$139.29M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-795.50
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
-17.82%
1M Leistung:
+3.04%
6M Leistung:
+14.76%
1J Leistung:
-17.14%
1-Tages-Spanne:
$14.22
$17.75
1-Wochen-Bereich:
$14.22
$24.67
52-Wochen-Spanne:
$6.53
$24.67
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.91 | 153.99M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Will Seres Therapeutics Inc. stock outperform Nasdaq indexShort Setup & Advanced Swing Trade Entry Plans - baoquankhu1.vn
What’s next for Seres Therapeutics Inc. stockProfit Target & Low Risk High Reward Ideas - Lancaster City Council
All You Need to Know About Seres Therapeutics (MCRB) Rating Upgrade to Buy - Yahoo Finance
Is Seres Therapeutics Inc. in a bullish channelJuly 2025 Market Mood & Free Technical Confirmation Trade Alerts - Lancaster City Council
Biotech Stocks Surge After Hours: CAPR, TMDX Lead Gains Amid Trial Updates And Earnings Momentum - RTTNews
Is It Too Early to Call Recovery in Seres Therapeutics Inc.Watch List & High Win Rate Trade Tips - beatles.ru
Seres Therapeutics (MCRB) Surges on Nestlé's $760 Million Offer - GuruFocus
Seres Therapeutics soars on report of takeover offer - MSN
Seres Therapeutics soars on report of takeover offer (MCRB:NASDAQ) - Seeking Alpha
Premarket Movers: RAPP, MCRB, JAGX. MEIP… - RTTNews
Seres Therapeutics Inc. Added to High Probability Setup ListWeekly Stock Summary & Low Volatility Stock Recommendations - beatles.ru
Charles Schwab Investment Management Inc. Sells 31,718 Shares of Seres Therapeutics, Inc. $MCRB - MarketBeat
Seres Therapeutics (MCRB)'s Technical Outlook is Bright After Key Golden Cross - MSN
Seres Therapeutics Inc. stock outlook for YEAR2025 Retail Activity & Safe Investment Capital Preservation Plans - Newser
Evaluating Seres Therapeutics Inc. with trendline analysisDividend Hike & Reliable Trade Execution Plans - Newser
tick level data insight on seres therapeutics inc. volatility2025 Top Gainers & AI Enhanced Trading Alerts - Newser
What candlestick patterns are forming on Seres Therapeutics Inc.Weekly Gains Summary & Growth Oriented Trading Recommendations - Newser
Is it time to cut losses on Seres Therapeutics Inc.July 2025 Highlights & Daily Stock Trend Watchlist - Newser
Ranking Seres Therapeutics Inc. among high performing stocks via tools2025 Volatility Report & Free Technical Confirmation Trade Alerts - Newser
Pattern recognition hints at Seres Therapeutics Inc. upsideMarket Sentiment Summary & Stepwise Entry/Exit Trade Alerts - Newser
Visual analytics tools that track Seres Therapeutics Inc. performanceJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Using Bollinger Bands to evaluate Seres Therapeutics Inc.Day Trade & Free Weekly Watchlist of Top Performers - Newser
How to read the order book for Seres Therapeutics Inc.Earnings Overview Report & Technical Pattern Based Signals - Newser
Volume spikes in Seres Therapeutics Inc. stock – what they mean2025 Market Outlook & Fast Entry and Exit Trade Plans - Newser
Is There Enough Volume to Lift Seres Therapeutics Inc.July 2025 Outlook & Real-Time Buy Zone Alerts - beatles.ru
Has Seres Therapeutics Inc. formed a bullish divergenceIndex Update & Long-Term Growth Plans - Newser
Seres Therapeutics receives $50 million from Nestlé Health Science - MSN
Earnings visualization tools for Seres Therapeutics Inc.2025 Short Interest & Target Return Focused Stock Picks - Newser
What machine learning models say about Seres Therapeutics Inc.2025 Volatility Report & Stepwise Swing Trade Plans - Newser
Seres Therapeutics Inc. stock momentum explainedJuly 2025 Closing Moves & Verified Momentum Stock Ideas - Newser
How to integrate Seres Therapeutics Inc. into portfolio analysis tools - Newser
Is Seres Therapeutics Inc. still worth holding after the dipEarnings Beat & Verified High Yield Trade Plans - Newser
Tick level data insight on Seres Therapeutics Inc. volatilityJuly 2025 Drop Watch & Community Shared Stock Ideas - Newser
Is now a turning point for Seres Therapeutics Inc.July 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - Newser
Full technical analysis of Seres Therapeutics Inc. stock2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - Newser
Can Seres Therapeutics Inc. be the next market leaderPortfolio Value Report & Fast Moving Stock Watchlists - خودرو بانک
Custom strategy builders for tracking Seres Therapeutics Inc.Sell Signal & Stock Market Timing Techniques - Newser
Is Seres Therapeutics Inc. a good stock for dollar cost averaging2025 Macro Impact & Precise Swing Trade Entry Alerts - خودرو بانک
Is Seres Therapeutics Inc. affected by consumer sentimentTrend Reversal & Weekly High Return Stock Opportunities - خودرو بانک
What MACD signals say about Seres Therapeutics Inc.Gold Moves & Long-Term Growth Portfolio Plans - Newser
Statistical indicators supporting Seres Therapeutics Inc.’s strength2025 Support & Resistance & Stock Market Timing Techniques - Newser
Top chart patterns to watch in Seres Therapeutics Inc.July 2025 Review & Weekly Watchlist for Consistent Profits - Newser
What is Seres Therapeutics Inc. s debt to equity ratioQuarterly Earnings Summary & Weekly Hot Stock Watchlists - خودرو بانک
What moving averages say about Seres Therapeutics Inc.July 2025 Market Mood & AI Forecasted Stock Moves - Newser
Market Pulse: Is Seres Therapeutics Inc. backed by strong institutional buyingTrade Analysis Report & Target Return Focused Picks - خودرو بانک
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):